Background: An advanced interatrial block (aIAB) is seen on the ECG as the combination of a P wave duration >120 ms and biphasic P wave morphology in the inferior leads. It is considered a marker of an electromechanically dysfunctional left atrium (LA) and hence a risk factor for supraventricular arrhythmias and heart failure (HF).
Patients and Methods:
An echocardiogram and a surface ECG were performed on a total of 51 HF patients in sinus rhythm (31 (61%) with HF with preserved ejection fraction (HFpEF), 20 (39%) with HF with reduced ejection fraction (HFrEF)) diagnosed per the current guidelines, and 20 sex-matched healthy controls. Echocardiographic parameters of LA structure and function were measured. ECG measurements were performed digitally with an electronic calliper.
Results: Prevalence of aIAB was 11% (n=8) in the studied group, significantly greater in HFpEF patients, compared to HFrEF patients and healthy controls (88% vs. 0% vs. 12%, p=0.025, Figure 1 ). The HFpEF patients formed an aIAB HFpEF subgroup (n=7) that was compared to two control groups, both without P wave duration >120 ms or biphasic P wave morphology in the inferior leads: age-and sex-matched HFpEF patients (n=7) and sex-matched healthy controls (n=12). Based on this subanalysis, the aIAB patients had a significantly higher occurrence of paroxysmal atrial fibrillation (healthy controls vs. HFpEF controls vs. aIAB: 0% vs. 43% vs. 86%, p<0.0001, Table 1 ). This subgroup also had the largest LA volumes (26.6 (18.7, 29.6) vs. 37.6 (32.7, 54.1) vs. 46.4 (41.4, 50.6 ) ml/m2, healthy controls vs. HFpEF controls vs. aIAB, respectively, p<0.0001, Conclusion: This pilot study relates aIAB to the HFpEF part of the HF spectrum. Significant differences in LA structural and functional characteristics suggest that aIAB may be a useful parameter for determining a clinically relevant subgroup of HFpEF patients, however an analysis of a larger patient cohort would be required to further establish these findings. Advanced interatrial block may be a useful parameter for determining a clinically relevant subgroup of heart failure patients with preserved ejection fraction -a pilot study
